XORTX 6-K incorporates legal opinions into F-3 (File 333-269429)

Q: Which exhibits were incorporated into the F-3 for XRTX?

Exhibits 99.2 and 99.3 , legal opinions on the legality of securities from Dentons Canada LLP and Troutman Pepper Locke LLP.

Q: What is the F-3 file number for XRTX?

The Registration Statement on Form F-3 has File No. 333-269429 .

Q: Who signed the Form 6-K for XRTX and when?

It was signed by Allen Davidoff , President and Chief Executive Officer, on October 31, 2025 .

Q: What additional document is listed in the 6-K exhibits?

A press release dated October 29, 2025 is listed as Exhibit 99.1 .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

XORTX Therapeutics Inc. filed a Form 6-K. The filing incorporates Exhibits 99.2 and 99.3 by reference into the company’s Registration Statement on Form F-3 (File No. 333-269429), adding legal opinions regarding the legality of securities being registered from Dentons Canada LLP and Troutman Pepper Locke LLP.

The exhibit index also lists a press release dated October 29, 2025 (Exhibit 99.1). The report is signed by President and Chief Executive Officer Allen Davidoff on October 31, 2025. This is an administrative update linking legal opinions to the existing F-3 shelf.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 10/31/2025 - 04:15 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-40858

XORTX THERAPEUTICS INC.

(Translation of registrant’s name into English)

3710 – 33^rd Street NW

Calgary, Alberta T2L 2M1

Canada

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

x   Form 20-F                      ¨   Form 40-F

INCORPORATION BY REFERENCE

Exhibits 99.2 and 99.3 to this report on Form 6-K are hereby incorporated by reference as an Exhibit to the Registration Statement on Form F-3 of XORTX Therapeutics Inc. (File No. 333-269429), as amended and supplemented.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		XORTX Therapeutics Inc.
		(Registrant)

Date:  October 31, 2025	By:	/s/ Allen Davidoff
		Name:    Allen Davidoff
		Title:      President and Chief Executive Officer

Form 6-K Exhibit Index

Exhibit Number		Document Description
99.1		Press Release of the Registrant, dated October 29, 2025
99.2		Opinion of Dentons Canada LLP, regarding legality of securities being registered
99.3		Opinion of Troutman Pepper Locke LLP, regarding the legality of the securities being registered

Source: View Original Filing on SEC EDGAR

FAQ

What did XRTX file on this Form 6-K?

XORTX filed a Form 6-K incorporating Exhibits 99.2 and 99.3 into its Form F-3, and listing a press release as Exhibit 99.1.

Which exhibits were incorporated into the F-3 for XRTX?

Exhibits 99.2 and 99.3, legal opinions on the legality of securities from Dentons Canada LLP and Troutman Pepper Locke LLP.

What is the F-3 file number for XRTX?

The Registration Statement on Form F-3 has File No. 333-269429.

Who signed the Form 6-K for XRTX and when?

It was signed by Allen Davidoff, President and Chief Executive Officer, on October 31, 2025.

What additional document is listed in the 6-K exhibits?

A press release dated October 29, 2025 is listed as Exhibit 99.1.

Does this 6-K describe an offering amount or proceeds for XRTX?

No. It records incorporation of legal opinions into the existing Form F-3 and lists a press release.